{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-30",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 2
    }
  },
  "results": [
    {
      "safetyreportversion": "2",
      "safetyreportid": "20435451",
      "primarysourcecountry": "US",
      "transmissiondateformat": "102",
      "transmissiondate": "20220423",
      "reporttype": "1",
      "serious": "2",
      "seriousnessdeath": "2",
      "seriousnesslifethreatening": "2",
      "seriousnesshospitalization": "2",
      "seriousnessdisabling": "2",
      "seriousnesscongenitalanomali": "2",
      "seriousnessother": "2",
      "receivedateformat": "102",
      "receivedate": "20220206",
      "receiptdateformat": "102",
      "receiptdate": "20220318",
      "fulfillexpeditecriteria": "2",
      "companynumb": "2022A051068",
      "duplicate": "1",
      "reportduplicate": {
        "duplicatesource": "MC USA",
        "duplicatenumb": "22US0006932"
      },
      "primarysource": {
        "reportercountry": "US",
        "qualification": "5"
      },
      "sender": {
        "sendertype": "2",
        "senderorganization": "FDA-Public Use"
      },
      "receiver": {
        "receivertype": "6",
        "receiverorganization": "FDA"
      },
      "patient": {
        "patientsex": "2",
        "reaction": [
          {
            "reactionmeddraversionpt": "24.1",
            "reactionmeddrapt": "Chronic obstructive pulmonary disease",
            "reactionoutcome": "6"
          }
        ],
        "drug": [
          {
            "drugcharacterization": "1",
            "medicinalproduct": "FASENRA",
            "drugbatchnumb": "ASKU",
            "drugauthorizationnumb": "761070",
            "drugstructuredosagenumb": "30",
            "drugstructuredosageunit": "003",
            "drugseparatedosagenumb": "1",
            "drugintervaldosageunitnumb": "8",
            "drugintervaldosagedefinition": "803",
            "drugadministrationroute": "058",
            "drugindication": "Chronic obstructive pulmonary disease",
            "drugstartdateformat": "602",
            "drugstartdate": "2021",
            "actiondrug": "4",
            "activesubstance": {
              "activesubstancename": "BENRALIZUMAB"
            },
            "openfda": {
              "application_number": [
                "BLA761070"
              ],
              "brand_name": [
                "FASENRA"
              ],
              "generic_name": [
                "BENRALIZUMAB"
              ],
              "manufacturer_name": [
                "AstraZeneca Pharmaceuticals LP"
              ],
              "product_ndc": [
                "0310-1730",
                "0310-1830",
                "0310-1745"
              ],
              "product_type": [
                "HUMAN PRESCRIPTION DRUG"
              ],
              "route": [
                "SUBCUTANEOUS"
              ],
              "substance_name": [
                "BENRALIZUMAB"
              ],
              "rxcui": [
                "1989104",
                "1989109",
                "2205632",
                "2205634",
                "2679499",
                "2679502"
              ],
              "spl_id": [
                "b78fbf2b-888c-41e2-bdab-cb5cd1ebb8fe"
              ],
              "spl_set_id": [
                "da6aca1a-19ed-44a4-abb7-696c7d58b784"
              ],
              "package_ndc": [
                "0310-1730-30",
                "0310-1730-85",
                "0310-1830-30",
                "0310-1830-85",
                "0310-1745-01",
                "0310-1745-95"
              ],
              "nui": [
                "N0000193803",
                "N0000193802"
              ],
              "pharm_class_epc": [
                "Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]"
              ],
              "pharm_class_moa": [
                "Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA]"
              ],
              "unii": [
                "71492GE1FX"
              ]
            }
          },
          {
            "drugcharacterization": "1",
            "medicinalproduct": "FASENRA",
            "drugbatchnumb": "ASKU",
            "drugauthorizationnumb": "761070",
            "drugstructuredosagenumb": "30",
            "drugstructuredosageunit": "003",
            "drugseparatedosagenumb": "1",
            "drugintervaldosageunitnumb": "8",
            "drugintervaldosagedefinition": "803",
            "drugadministrationroute": "058",
            "drugindication": "Asthma",
            "drugstartdateformat": "602",
            "drugstartdate": "2021",
            "actiondrug": "4",
            "activesubstance": {
              "activesubstancename": "BENRALIZUMAB"
            },
            "openfda": {
              "application_number": [
                "BLA761070"
              ],
              "brand_name": [
                "FASENRA"
              ],
              "generic_name": [
                "BENRALIZUMAB"
              ],
              "manufacturer_name": [
                "AstraZeneca Pharmaceuticals LP"
              ],
              "product_ndc": [
                "0310-1730",
                "0310-1830",
                "0310-1745"
              ],
              "product_type": [
                "HUMAN PRESCRIPTION DRUG"
              ],
              "route": [
                "SUBCUTANEOUS"
              ],
              "substance_name": [
                "BENRALIZUMAB"
              ],
              "rxcui": [
                "1989104",
                "1989109",
                "2205632",
                "2205634",
                "2679499",
                "2679502"
              ],
              "spl_id": [
                "b78fbf2b-888c-41e2-bdab-cb5cd1ebb8fe"
              ],
              "spl_set_id": [
                "da6aca1a-19ed-44a4-abb7-696c7d58b784"
              ],
              "package_ndc": [
                "0310-1730-30",
                "0310-1730-85",
                "0310-1830-30",
                "0310-1830-85",
                "0310-1745-01",
                "0310-1745-95"
              ],
              "nui": [
                "N0000193803",
                "N0000193802"
              ],
              "pharm_class_epc": [
                "Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]"
              ],
              "pharm_class_moa": [
                "Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA]"
              ],
              "unii": [
                "71492GE1FX"
              ]
            }
          },
          {
            "drugcharacterization": "1",
            "medicinalproduct": "DALARGIN",
            "drugstructuredosagenumb": "500",
            "drugstructuredosageunit": "004",
            "drugseparatedosagenumb": "1",
            "drugintervaldosageunitnumb": "1",
            "drugintervaldosagedefinition": "804",
            "drugadministrationroute": "048",
            "drugindication": "Hypersensitivity",
            "actiondrug": "4",
            "activesubstance": {
              "activesubstancename": "DALARGIN"
            }
          }
        ]
      }
    }
  ]
}